A Phase II Study Of Epothilone B Analog BMS-247550 (NSC 710428D) In Patients With Advanced Colorectal Carcinoma
- Determine the objective response rate in patients with locally recurrent or metastatic
colorectal cancer treated with BMS-247550.
- Determine the toxicity of this drug in these patients.
- Determine the duration of response, median and overall survival, and time to
progression in patients treated with this drug.
OUTLINE: This is a multicenter study.
Patients receive BMS-247550 IV over 3 hours on day 1. Treatment repeats every 21 days in the
absence of disease progression or unacceptable toxicity.
Patients are followed every 6 weeks.
PROJECTED ACCRUAL: A total of 21-50 patients will be accrued for this study within 8-10
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Response rate of BMS-247550 in colon cancer
Hedy L. Kindler, MD
University of Chicago
United States: Federal Government
|Albert Einstein Comprehensive Cancer Center||Bronx, New York 10461|
|University of Chicago Cancer Research Center||Chicago, Illinois 60637|
|Loyola University Medical Center||Maywood, Illinois 60153|
|Ingalls Memorial Hospital||Harvey, Illinois 60426|
|Lutheran General Cancer Care Center||Park Ridge, Illinois 60068|
|Evanston Northwestern Health Care||Evanston, Illinois 60201|
|Louis A. Weiss Memorial Hospital||Chicago, Illinois 60640|
|Lakeland Medical Center - St. Joseph||Saint Joseph, Michigan 49085|
|University of Illinois at Chicago||Chicago, Illinois 60612|
|Oncology/Hematology Associates of Central Illinois, P.C.||Peoria, Illinois 61602|
|Central Illinois Hematology Oncology Center||Springfield, Illinois 62701|
|Fort Wayne Medical Oncology and Hematology, Inc.||Fort Wayne, Indiana 46885-5099|
|Michiana Hematology/Oncology P.C.||South Bend, Indiana 46617|
|Decatur Memorial Hospital Cancer Care Institute||Decatur, Illinois 62526|
|LaGrange Memorial Hospital||LaGrange, Illinois 60525|